Objective: To evaluate the effectiveness of opioids and/or pregabalin on patient-reported outcomes among fibromyalgia (FM) patients based on levels of improvement. Methods: A total of 1,421 FM patients were identified, with 3,082 observational periods of opioids with or without pregabalin use between April 2008 and February 2015. Patients were categorized by opioids, and pregabalin with and without opioids; opioids were designated by morphine equivalent dose (MED) of ≤ 20 (low MED), > 20 to < 100 (moderate MED), ≥ 100 (high MED), and pregabalin doses of ≤ 150 mg, 151 to 300 mg, and 301 to 450 mg. Proportions of patients meeting clinically relevant thresholds of ≥ 30% and ≥ 50% improvement for pain interference (ability to enjoy life; activity; mood; relationships; sleep), pain severity, and fatigue were compared among treatments, and area under the curve (AUC) for improvement and worsening of effects was determined, enabling ranking of treatments. Further analysis compared pregabalin doses. Results: Pregabalin without opioids resulted in the highest proportions of patients with ≥ 30% improvement on all pain items and pain interference with "ability to enjoy life," "activity" "mood," and "sleep." For the ≥ 50% threshold, pregabalin alone was highest for all pain interference items and for "average pain" and "worst pain." Pregabalin was consistently lowest across thresholds for fatigue, but showed better results combined with moderate MED opioids. Pregabalin doses recommended for treatment of FM (151 to 450 mg) generally resulted in the highest proportion of patients achieving thresholds relative to opioids. The AUC results were consistent with thresholds; pregabalin without opioids resulted in the greatest benefits with regard to improvement, with the highest ranking for overall improvement and overall effects. Conclusion: Pregabalin without opioids provided the most favorable outcomes overall based on ≥ 30% and ≥ 50% improvement thresholds and AUC, with support for moderate MED opioids + pregabalin in patients suffering from fatigue. While most patients took less than recommended pregabalin doses, higher doses may lead to improved outcomes. &
INTRODUCTION
Fibromyalgia (FM) is a chronic disorder that is thought to result from a dysfunction of central pain processing pathways, 1, 2 which results in the hallmark symptoms of widespread musculoskeletal pain, joint stiffness, and fatigue. In addition to these symptoms, FM is characterized by sleep disturbances, depression, and cognitive difficulties. 3, 4 As FM severity increases from mild to incapacitating, the disease inflicts a greater burden on patients as shown by its associations with reductions in daily function and quality of life, lost productivity, and higher healthcare resource use. [5] [6] [7] Recommendations for the management of FM include use of pharmacologic agents from a variety of therapeutic classes, including antidepressants and anticonvulsants, but specifically recommend against the use of opioids except for weak opioids such as tramadol. [8] [9] [10] [11] In the United States, the Food and Drug Administration (FDA) has approved 3 drugs for the treatment of FM: 2 antidepressants (duloxetine and milnacipran) and an anticonvulsant (pregabalin). However, treatment of FM remains challenging, and studies have shown low or ineffective use of approved or recommended therapies, with opioids consistently reported as the most frequently prescribed pharmacologic agent despite little evidence for their efficacy. 2, [12] [13] [14] [15] Indeed, studies have suggested that opioid use may be associated with higher healthcare resource utilization and costs among patients with FM. 15, 16 Nevertheless, an older survey among patients with FM found that these patients perceived opioids to be among the most effective therapies. 17 Thus, since there remains a need for evaluating the effectiveness of opioids, the objective of this study is to characterize and compare the effectiveness of opioids with pregabalin both in the absence and presence of concomitant opioid use across a range of patient-reported outcomes relevant to pain, daily function, and fatigue using 2 complementary methods that can enrich the interpretation of effects.
METHODS

Data Source and Population
The data source for this retrospective analysis was cliniclevel data from the ProCare Systems network of chronic pain clinics in Michigan between April 2008 and February 2015. All patient data were de-identified and fully compliant with the Health Insurance Portability and Accountability Act (HIPAA).
Patients with FM were identified using traditional selection criteria and predictive modeling as previously described. 18 All patients were required to have Class 1 FM, ie, regional FM with classic symptoms, according to the 4 identified classes that reflect symptom severity and comorbidities, pain regions, and treatment intensity. 19 Patients were also required to have been prescribed opioids and/or pregabalin and have completed baseline and follow-up PRISM TM Pain Health Assessment (PHA). PRISM TM is a care management system that was created by ProCare Systems to provide real-time clinical data to inform patient care and to track outcomes. The PHA is part of the PRISM system and a self-report measure that contains core outcome domains for evaluating efficacy and effectiveness of treatments on disease presence, pain characteristics, physical function, and psychosocial function.
Patients were assigned to groups stratified by their average morphine equivalent dose (MED: low, MED ≤ 20; moderate, MED > 20 to < 100; and high, MED ≥ 100), and subgroups to investigate outcomes at varying levels of pregabalin dose, including ≤ 150 mg, 151 to 300 mg, and 301 to 450 mg; the recommended doses of pregabalin for the treatment of FM are 300 to 450 mg. 20 Calculations of MED were performed using common guidelines. 21 Observational time (ie, days between baseline and follow-up PHAs) was limited to 56 to 365 days.
Outcomes
Outcomes consisted of questions from the PHA, including 5 items relating to pain interference (ability to enjoy life, activity in general, mood, relationships with others, and sleep), 3 for measuring pain severity (average pain in the last 4 weeks, pain right now while completing your PHA, and worst pain in the last 4 weeks), and 2 for fatigue (Do you feel tired? Do you feel worn out?). The questions on pain severity and interference in the PHA are closely aligned with the Brief Pain Inventory, a validated measure of pain severity and interference using a 0-to-10 numeric rating scale (NRS; 0 = no pain or interference, 10 = worst possible pain or complete interference). 22 Questions that address fatigue are similar to those that comprise the "Vitality" scale of the validated 36-item Short Form Health Survey SF-36. 23 These outcomes are consistent with general recommendations of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) 24 as well as more specific recommendations for FM by the Outcome Measures in Rheumatology (OMERACT) group.
25,26
Analysis A response was considered any improvement from baseline (change from baseline of ≥ 0) on the assessed outcome. The proportions of responders who reported improvement of at least 30% and 50% from baseline were compared between treatment arms. These thresholds are consistent with IMMPACT recommendations for clinically relevant improvements in pain, with the 30% and 50% thresholds reflecting moderate and substantial improvements, respectively. 27 Statistical significance for all comparisons was based on 95% confidence intervals (CIs) calculated (bias corrected and accelerated method) using bootstrapping with 10,000 iterations. Additionally, efficacy was evaluated using an areaunder-the-curve (AUC) adaptation of a cumulative proportion of responder's analysis (CPRA). The CPRA is a method that represents the cumulative proportion of patients who reach a specific response, calculated across the range of possible responses for improvement from baseline. 28 As has been previously proposed, 29, 30 the application of AUC to a responder analysis enriches the interpretation of improvement in selected outcomes and encompasses all relevant responder information. Graphically, the change in the outcome of interest is depicted on the x-axis, with the proportion of patients on the yaxis. All possible cutoff points of improvement can be incrementally represented, allowing for a visual representation of change scores. Extending this concept, multiple groups can be included within the same graph and subsequently compared for patient responses to treatment. For each outcome, the AUC was estimated based on percentage improvement on the outcome. In the current analysis, the AUC for each item was derived using Simpson's rule. 31 Differences in the derived AUCs were compared between treatments, with statistical significance based on calculated 95% CIs according to a bias corrected and accelerated method using bootstrapping with 10,000 iterations.
RESULTS
Population Characteristics
A total of 1,421 unique FM patients taking opioids and/or pregabalin were identified, with 3,082 pre-/ post-observational periods. Of these observations, 2,396 (77.7%) were female with a mean (SD) age of 50.5 (12.7) years ( Table 1 ). The time under assessment was approximately 180 days and was similar among the treatments. Because there were some gaps in opioid and pregabalin prescriptions during patients' assessment periods, the mean percentage time on opioids and pregabalin represents the fraction of time in days that patient prescriptions could be accounted for over the entire assessment period, and ranged from 50% to 99%. The number of opioid prescriptions tended to be higher across increasing levels of MED (see Table 1 ). The mean MED for all patients taking opioids was 60.6 AE 111.4, and the mean pregabalin dose was 159.7 AE 140.8 mg. On average, pregabalin dose was higher in patients taking a combination of opioids + pregabalin relative to pregabalin without opioids and increased across the MED levels (see Table 1 ).
When pregabalin doses were stratified across all patients by strata of ≤ 150 mg, 151 to 300 mg, 301 to 450 mg, and 451 to 600 mg (see Table 1 ), the largest proportions of patients were taking ≤ 150 mg, ranging from approximately 52% (high MED opioids, pregabalin) to 77% (pregabalin without opioids). Few patients (n = 14; 3.4%) were in the 301 to 450 mg FDA recommended dose group. Generally, the proportions of patients taking opioids + pregabalin were higher for all dose groups than patients taking pregabalin alone.
Analysis by Response Thresholds
Pregabalin without opioid use resulted in the highest proportions of patients achieving ≥ 30% improvement across all pain items (Table 2) , and was statistically significant relative to low MED opioids + pregabalin for "pain right now while completing your PHA" (13.2%, 95% CI 0.8%, 27.2%; P < 0.05). While pregabalin without opioids had a low ranking for both of the fatigue items, there were no significant differences for any of the treatment comparisons.
On pain interference (see Table 2 ), pregabalin without opioids also resulted in the highest proportions of patients who achieved ≥ 30% improvement except for "relationships with others," which was highest with moderate MED opioids + pregabalin. Pairwise comparisons showed that differences between treatments were significant with pregabalin for "activity in general" relative to low MED opioids (15.0%, 95% CI 0.9%, 30.5%), moderate MED opioids (15.4%, 95% CI 1.1%, 31.1%), 52 (40) 110 (78) 150 (83) 60 (28) 1,194 (593) 1057 (491) 459 ( Similar superscript symbols indicate significant differences (P < 0.05) between the indicated treatments for the outcomes shown in each row. Values reflect total number of patients in the treatment group with nonmissing data for the item evaluated. MED, morphine equivalent dose.
and high MED opioids (16.7%, 95% CI 2.3%, 32.4%) (all P < 0.05). The difference was also significant for high MED opioids + pregabalin relative to low MED opioids + pregabalin (16.2%, 95% CI 2.5%, 30.9%; P < 0.04). For "relationships with others," pairwise comparisons showed that the differences were significant, with higher proportions reporting ≥ 30% improvement (see Table 2 ), with moderate MED opioids + pregabalin relative to high MED opioids (9.4%, 95% CI 0.7%, 18.7%), low MED opioids (9.7%, 95% CI 1.5%, 18.2%), and low MED opioids + pregabalin (13.1%, 95% CI 1.9%, 23.9%) (all P < 0.05). Pregabalin in the absence of opioids resulted in the highest proportions of patients with ≥ 50% improvement in "average pain" and "worst pain," although none of the differences with other groups was significant (see Table 2 ). While pregabalin without opioids was significant vs. high MED opioids + pregabalin for "ability to enjoy life" (14.2%, 95% CI 4.5%, 28.5%; P < 0.05), it had the lowest ranking for ≥ 50% improvement in fatigue items, with differences in "worn out" that were significant relative to low MED opioids (À9.8%, 95% CI À15.3%, À2.1%) and moderate MED opioids + pregabalin (À10.2%, 95% CI À1.0%, À18.1%) (both P < 0.05).
While pregabalin, with or without opioids, at a dose of 301 to 450 mg resulted in the highest proportions of patients achieving ≥ 30% improvement on the 2 psychosocial items ("mood" and "relationships with others"), the 151 to 300 mg dose showed the best results on the other pain interference items (Table 3) . Opioids resulted in the lowest proportions except for "sleep," for which it ranked next to lowest, with the highest pregabalin dose ranked last. On pain severity (see Table 3 ), the highest pregabalin dose had the best effects on "average pain" and "pain right now," but very low proportions of patients reported ≥ 30% improvement on "worst pain." For patients reporting an improvement of at least 50% from baseline, the pregabalin doses of 151 to 300 mg and 301 to 450 mg were found to have the greatest proportion in all 10 items, split amongst the 3 domains, pain interference, pain severity, and fatigue (see Table 3 ). Figure 1 presents sample profiles for responders and nonresponders using the top 4 treatments for "activity in general." This figure visualizes the comparison across the full range of responses and assists in the simultaneous assessment of improvement and worsening, with higher curves for improvement and lower curves for worsening the preferred outcomes. The area under each Similar superscript symbols indicate significant differences (P < 0.05) between the indicated treatments for the outcomes shown in each row. MED, morphine equivalent dose.
Analysis by Area Under the Curve
line represents the AUC, and the area between the 2 lines expresses the differences in AUC response between treatments. As shown, pregabalin results in consistently better responses across the range of improvement levels, and results in worsening similar to or less than with the comparator opioid groups. Similar results were generally observed for the other outcomes (data not shown). The derived AUCs for percentage improvement in pain and fatigue items are shown in Figure 2 . While the highest AUCs for pain were observed for pregabalin, the greatest effects on fatigue were observed with moderate MED opioids + pregabalin. These AUCs can be interpreted as if all responders were improved by the same percentage. For example, the AUC of 20.4% with pregabalin for "pain right now" suggests that pregabalin responders had on average a 20.4% reduction in current pain. Similarly, Figure 2 also presents the AUCs for pain interference, and shows that pregabalin results in the highest AUC for all Figure 1 . Sample response profiles illustrating the analysis based on area-under-the-curve (AUC). The gray area represents the difference in the AUC between the compared treatments among nonresponders (worsening) and responders (improvement); results are shown for "activity in general" for the top 4 ranked treatments, with all other variables analyzed in a similar manner. MED, morphine equivalent dose.
interference outcomes except for "relationships," which was highest with moderate MED opioids + pregabalin. Figure 3 provides a holistic perspective among the treatments by summarizing patient responses along the entire range of responders and nonresponders by rank of improvement ( Figure 3A) , rank of worsening (Figure 3B) , and the total effect ( Figure 3C ) as represented by summation of improvement and worsening; the higher the rank, the better the effect (greater improvement and less worsening). The top 3 treatments as determined by their total effect are pregabalin, high MED opioids + pregabalin, and high MED opioids.
Statistical comparison of pairwise differences in percentage improvement for the treatment having the greatest response are shown in Figure 4 for pain severity and fatigue, and Figure 5 for pain interference. Treatment groups that included pregabalin, either in the absence of or combined with opioids, showed the greatest differences in effects. Generally, where the differences are statistically significant, patients taking pregabalin without opioids exhibited an improvement of 5% to 15% greater than the other treatments (ie, high MED opioids + pregabalin, high MED opioids, moderate MED opioids, and moderate MED opioids + pregabalin); patients taking high MED opioids + pregabalin reported an improvement of 4% to 10% greater than the other treatments; patients taking moderate MED opioids + pregabalin improved 1% to 5% more than patients taking moderate or high MED opioids alone.
Placing the AUC results in a similar context as the main treatment comparisons, Figure 6 shows that pregabalin doses of 301 to 450 mg and 151 to 300 mg were the top 2 ranked subgroups for overall total effect, improvement, and worsening. Opioids were third ranked based on patients reporting less worsening than pregabalin doses of ≤ 150 mg.
DISCUSSION
The few studies on opioids for the treatment of FM have suggested that while responders to the weak opioid tramadol may have a reduction in pain but not in healthrelated quality of life, 32 opioids may have contributed to increased resource use and costs, or less favorable outcomes. 15, 16, 33 The current study expands on the evaluated effectiveness of opioids for FM by showing that although opioids may provide benefits in pain and pain interference outcomes, treatment with pregabalin, which is approved for the treatment of FM, appeared to provide more favorable outcomes relative to opioids. Notably, this responder analysis not only used improvement thresholds to show that the benefits represent clinically relevant outcomes that affect patients' daily lives, but also included an approach that takes into account the entire response profile for patients who reported improvement as well as for those who worsened.
Assessment of worsening is an infrequently evaluated concept that provides broader comparative characterization of treatment effects and enables ranking of treatment modalities based on their overall appropriateness. For example, while responders in the moderate MED opioids + pregabalin group exhibited favorable outcomes for improvement, nonresponders in this treatment group seemed to worsen to a greater extent than with other treatments, resulting in moderate MED opioids + pregabalin having the lowest ranking for overall worsening relative to other treatments. In contrast, pregabalin in the absence of opioids had the highest ranking for overall improvement as well as for overall effects, with responders not only achieving, on average, improvements in pain that ranged from 11% for "worst pain" to 20% for "pain right now," but average improvements of 18% to 26% for pain interference items.
Pregabalin doses of 301 to 450 mg generally provided the most benefit to patients compared with other pregabalin doses as well as with patients prescribed only opioids. Interestingly, the mean dose of pregabalin increased as the opioid MED increased, which may be consistent with a greater need for pain control. These results are in concordance with a recent review that reported pregabalin ≥ 300 mg results in major reductions in pain accompanied by ancillary improvements in functional and quality-of-life outcomes. 34 However, in the current study, not only was the mean pregabalin dose, 159.7 mg, approximately half of the lowest recommended dose for FM treatment, 20 but the largest proportion of patients (60.5%) were taking pregabalin ≤ 150 mg; the 150 mg dose also had the lowest ranking with regard to total effects. While use of low pregabalin doses (ie, less than the recommended dose) in the clinical setting has consistently been reported, [35] [36] [37] the reason for such suboptimal dosing is unclear. It should also be noted that very few patients were taking 451 to 600 mg, which exceeds the indicated dose range for FM.
20
The differences in the AUC (see Figures 4 and 5) can be interpreted as an indication of the treatment groups that were favored for each comparison across the evaluated outcomes, and the magnitude of the differences in response. Based on these differences, the domains that showed the greatest responses with pregabalin alone as well as when combined with opioids (ie, pain interference on "activity in general" and "sleep") were also those that are considered of importance by patients. 38, 39 The effects on sleep are not surprising given not only the reciprocal relationship between pain and sleep, [40] [41] [42] but that pregabalin has positive effects on sleep across a range of conditions, with these effects appearing to occur directly on sleep as well as through the reduction in pain, including in patients with FM. 43, 44 Such effects are especially important in FM, since sleep disturbances are a primary complaint among these patients even though there is little evidence supporting a role for sleep physiology in maintaining FM. 45 Pregabalin without opioids was also the treatment that resulted in the greatest benefits in reducing pain interference on "Mood." Despite the benefits of pregabalin on sleep and activity, pregabalin in the absence of opioids had a lower impact on fatigue than on other outcomes and also relative to the other treatment groups. This observation suggests that fatigue represents a multidimensional concept in FM that may not necessarily reflect the previously described mediation of fatigue through pain and sleep disturbance. 46 Nevertheless, this lack of effect on fatigue by pregabalin is not surprising given previous results suggesting that pregabalin does not reduce fatigue in FM.
47
STRENGTHS AND LIMITATIONS
A strength of this study is its use of data from clinical practice. However, its retrospective design rather than a randomized controlled trial represents a limitation, as does the fact that the population was from a limited geographic area, reducing generalizability. Another limitation is that longitudinal assessment was not performed in individual patients, since duration of treatment may affect the measured outcomes. Furthermore, it should also be considered that polypharmacy is common in FM patients for the treatment of FM itself as well as for comorbid conditions. 2, 48, 49 Thus, since many patients are likely to be taking other medications that are recommended or commonly used for treatment of FM (eg, antidepressants) in addition to pregabalin and opioids, the positive outcomes may have been impacted in part by medications other than pregabalin and/or opioids.
CONCLUSIONS
Pregabalin in the absence of opioids generally provided the most favorable outcomes in pain severity and pain interference among responders regardless of whether the results were based on clinically relevant thresholds of improvement from baseline (ie, ≥ 30% and ≥ 50%) or the entire response profile. However, while most patients took less than the recommended pregabalin doses, the preferential pregabalin doses for improvement and total effects are most likely between 151 and 450 mg, suggesting that higher doses than currently used by patients in the clinical setting may lead to better outcomes. Some consideration for the use of opioids in combination with pregabalin was also suggested, in particular, high MED opioids + pregabalin demonstrated positive outcomes with a favorable response profile.
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